PMID- 37697668
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20231127
IS  - 1349-9157 (Electronic)
IS  - 0449-3060 (Print)
IS  - 0449-3060 (Linking)
VI  - 64
IP  - 6
DP  - 2023 Nov 21
TI  - The Japanese nationwide cohort data of proton beam therapy for liver 
      oligometastasis in esophagogastric cancer patients.
PG  - 926-932
LID - 10.1093/jrr/rrad066 [doi]
AB  - A nationwide multicenter cohort study on particle therapy was launched by the 
      Japanese Society for Radiation Oncology in Japan in May 2016. We analyzed the 
      outcome of proton beam therapy (PBT) for liver oligometastasis of esophagogastric 
      cancers. Cases in which PBT was performed at all PBT facilities in Japan between 
      May 2016 and February 2019 were enrolled. The patients were selected based on the 
      following criteria: controlled primary cancer, liver recurrence without 
      extrahepatic tumors and no more than three liver lesions. Twenty-two males and 
      two females with a median age of 69 (range, 52-80) years and 35 lesions were 
      included. This study included 6 patients with esophageal and 18 patients with 
      gastric cancer. The median lesion size, fraction size and biological effective 
      dose (BED)10 were 32 (7-104) mm, 3.8 gray (relative biological effect)/fractions 
      (Gy (RBE)/fr) (2-8 Gy (RBE)/fr) and 96.9 (88.8-115.2) Gy, respectively. The 
      median follow-up period was 18 (4-47) months. The 1-, 2- and 3-year overall 
      survival (OS) rates were 75, 51.8 and 45.3%, respectively, and the median OS was 
      25.3 months. The 1-, 2- and 3-year cumulative local recurrence (LR) rates were 3, 
      6 and 6%, respectively. Patients' age (P < 0.01), performance status (P = 0.017) 
      and tumor size (P = 0.024) were significant OS-related factors. No Grade 3 or 
      higher adverse events (AEs) were observed. Owing to the low incidence of AEs and 
      the low LR cumulative incidence, PBT is a feasible option for liver 
      oligometastasis of esophagogastric cancers.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of The 
      Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
FAU - Yamaguchi, Hisashi
AU  - Yamaguchi H
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, 7-172 
      Yatsuyamada, Koriyama, Fukushima 963-8052, Japan.
FAU - Fukumitsu, Nobuyoshi
AU  - Fukumitsu N
AD  - Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton 
      Center, 1-6-8 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
FAU - Numajiri, Haruko
AU  - Numajiri H
AD  - Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennoudai, 
      Tsukuba, Ibaraki 305-8575, Japan.
FAU - Ogino, Hiroyuki
AU  - Ogino H
AD  - Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City 
      University West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508, 
      Japan.
FAU - Katoh, Norio
AU  - Katoh N
AD  - Department of Radiation Oncology, Hokkaido University Faculty of Medicine, 
      North-15 West-7, Kita-ku, Sapporo 060-8638, Japan.
FAU - Okimoto, Tomoaki
AU  - Okimoto T
AD  - Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Koto, Shingu-cho, 
      Tatsuno, Hyogo 679-5165, Japan.
FAU - Suzuki, Motohisa
AU  - Suzuki M
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, 7-172 
      Yatsuyamada, Koriyama, Fukushima 963-8052, Japan.
FAU - Sakurai, Hideyuki
AU  - Sakurai H
AD  - Department of Radiation Oncology, University of Tsukuba, 1-1-1 Tennoudai, 
      Tsukuba, Ibaraki 305-8575, Japan.
LA  - eng
GR  - JP16lm0103004/AMED/
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - J Radiat Res
JT  - Journal of radiation research
JID - 0376611
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - *Proton Therapy/adverse effects
MH  - *Esophageal Neoplasms/radiotherapy
MH  - *Stomach Neoplasms/radiotherapy
MH  - Cohort Studies
MH  - East Asian People
MH  - Liver
PMC - PMC10665303
OTO - NOTNLM
OT  - esophageal cancer
OT  - gastric cancer
OT  - gastrointestinal cancer
OT  - liver metastasis
OT  - proton beam therapy
COIS- None.
EDAT- 2023/09/12 06:41
MHDA- 2023/11/27 12:44
PMCR- 2023/09/11
CRDT- 2023/09/12 02:22
PHST- 2023/07/04 00:00 [received]
PHST- 2023/08/03 00:00 [revised]
PHST- 2023/11/27 12:44 [medline]
PHST- 2023/09/12 06:41 [pubmed]
PHST- 2023/09/12 02:22 [entrez]
PHST- 2023/09/11 00:00 [pmc-release]
AID - 7267602 [pii]
AID - rrad066 [pii]
AID - 10.1093/jrr/rrad066 [doi]
PST - ppublish
SO  - J Radiat Res. 2023 Nov 21;64(6):926-932. doi: 10.1093/jrr/rrad066.